Endo International (NASDAQ:ENDP) (TSE:ENL) released its quarterly earnings data on Thursday. The company reported $0.71 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.12, Briefing.com reports. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The firm had revenue of $745.00 million during the quarter, compared to analysts’ expectations of $694.93 million. During the same period last year, the business earned $0.91 earnings per share. Endo International’s revenue was down 5.3% compared to the same quarter last year. Endo International updated its FY 2018 guidance to $2.65-2.75 EPS and its FY18 guidance to $2.65-2.75 EPS.
Shares of ENDP stock opened at $13.49 on Friday. The company has a market capitalization of $3.59 billion, a P/E ratio of 3.51, a price-to-earnings-growth ratio of 1.54 and a beta of 0.65. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $18.50.
In related news, Director Roger H. Kimmel sold 26,074 shares of Endo International stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.80% of the company’s stock.
Several hedge funds have recently made changes to their positions in ENDP. Schroder Investment Management Group grew its holdings in shares of Endo International by 78.1% in the second quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock valued at $7,349,000 after purchasing an additional 327,775 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Endo International by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock valued at $23,074,000 after purchasing an additional 284,599 shares in the last quarter. Sivik Global Healthcare LLC acquired a new position in shares of Endo International in the second quarter valued at approximately $1,697,000. Arizona State Retirement System grew its holdings in shares of Endo International by 115.7% in the second quarter. Arizona State Retirement System now owns 293,200 shares of the company’s stock valued at $2,765,000 after purchasing an additional 157,252 shares in the last quarter. Finally, Capital Growth Management LP acquired a new position in shares of Endo International in the third quarter valued at approximately $2,356,000. Hedge funds and other institutional investors own 98.43% of the company’s stock.
ENDP has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Endo International from a “hold” rating to a “sell” rating in a research report on Monday, July 16th. Deutsche Bank set a $11.00 price target on shares of Endo International and gave the company a “buy” rating in a research report on Wednesday, July 18th. BidaskClub upgraded shares of Endo International from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 21st. Cantor Fitzgerald set a $12.00 price target on shares of Endo International and gave the company a “hold” rating in a research report on Monday, July 23rd. Finally, ValuEngine upgraded shares of Endo International from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 25th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. Endo International has an average rating of “Hold” and an average price target of $14.97.
COPYRIGHT VIOLATION NOTICE: “Endo International (ENDP) Announces Quarterly Earnings Results, Beats Expectations By $0.12 EPS” was first reported by Macon Daily and is the property of of Macon Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://macondaily.com/2018/11/10/endo-international-endp-announces-quarterly-earnings-results-beats-expectations-by-0-12-eps.html.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.